Barclays
NXTC icon

Barclays’s NextCure NXTC Stock Holding History

Barclays’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.1K Hold
5,626
– – ﹤0.01% 4246
2025
Q4 		$79.8K Hold
5,626
– – ﹤0.01% 4637
2025
Q3 		$33K Sell
5,626
-1
-0% -$5 ﹤0.01% 4863
2025
Q2 		$31.1K Hold
5,627
– – ﹤0.01% 4780
2025
Q1 		$32.4K Hold
5,627
– – ﹤0.01% 4704
2024
Q4 		$52.1K Hold
5,627
– – ﹤0.01% 4752
2024
Q3 		$92.5K Hold
5,627
– – ﹤0.01% 4590
2024
Q2 		$107K Sell
5,627
-2
-0% -$39 ﹤0.01% 3871
2024
Q1 		$151K Hold
5,629
– – ﹤0.01% 4258
2023
Q4 		$77K Hold
5,629
– – ﹤0.01% 4698
2023
Q3 		$87.1K Hold
5,629
– – ﹤0.01% 3643
2023
Q2 		$122K Hold
5,629
– – ﹤0.01% 3489
2023
Q1 		$100K Sell
5,629
-1
-0% -$19 ﹤0.01% 4177
2022
Q4 		$95.3K Sell
5,630
-44
-0.8% -$1.01K ﹤0.01% 4253
2022
Q3 		$187K Hold
5,674
– – ﹤0.01% 3248
2022
Q2 		$320K Sell
5,674
-400
-7% -$20.9K ﹤0.01% 3156
2022
Q1 		$354K Buy
6,074
+78
+1% +$4.88K ﹤0.01% 3106
2021
Q4 		$432K Sell
5,996
-201
-3% -$16.8K ﹤0.01% 3265
2021
Q3 		$501K Buy
6,197
+2,992
+93% +$262K ﹤0.01% 3198
2021
Q2 		$309K Buy
3,205
+32
+1% +$3.27K ﹤0.01% 3342
2021
Q1 		$381K Sell
3,173
-456
-13% -$66K ﹤0.01% 3349
2020
Q4 		$474K Sell
3,629
-239
-6% -$30.9K ﹤0.01% 3260
2020
Q3 		$407K Buy
3,868
+3,040
+367% +$374K ﹤0.01% 3381
2020
Q2 		$213K Buy
828
+341
+70% +$130K ﹤0.01% 4021
2020
Q1 		$216K Sell
487
-803
-62% -$429K ﹤0.01% 4240
2019
Q4 		$872K Buy
1,290
+1,136
+738% +$570K ﹤0.01% 3801
2019
Q3 		$56K Sell
154
-676
-81% -$220K ﹤0.01% 5856
2019
Q2 		$138K Buy
+830
New +$173K ﹤0.01% 5434

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Barclays's NXTC Position: Q1 2026 in Review

Barclays held its NextCure (NXTC) position steady in Q1 2026 at 5,626 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4246.

Barclays first reported a position in NXTC in Q2 2019 and has held it in 28 quarters since. The position peaked at $872K in Q4 2019. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Barclays held 5,626 shares of NextCure worth $60.1K as of Q1 2026.
  • Barclays left its NextCure share count unchanged in Q1 2026.
  • NextCure made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4246 holding.
  • Barclays first reported a position in NextCure in Q2 2019 and has held it in 28 quarters since.
  • Barclays's NextCure position peaked at $872K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.